Key result
Operative intervention alters ET-1, neuropeptide Y, and CGRP levels in children with CHD and PH.
Why the study?
This study aimed to explore changes in endothelin-1, plasma neuropeptide Y, and calcitonin gene-related peptide before and after operation in pediatric patients with congenital heart disease complicated with pulmonary hypertension.
Does operative intervention change the levels of ET-1, plasma neuropeptide Y, and CGRP in child patients with congenital heart disease complicated with pulmonary hypertension compared to conservative treatment?
Cohort (n=80)
Does operative intervention change the levels of ET-1, plasma neuropeptide Y, and CGRP in child patients with congenital heart disease complicated with pulmonary hypertension compared to conservative treatment?
ET-1, plasma neuropeptide Y, and CGRP levels correlate with systolic pulmonary arterial pressure and change significantly after operative intervention in children with CHD and PH, highlighting their potential as biomarkers for treatment efficacy.
Operative changes in ET-1, neuropeptide Y, and CGRP may indicate treatment response in pediatric CHD-PH; leaves open their validation as biomarkers in controlled trials.
This study aims to explore the changes in endothelin-1 (ET-1), plasma neuropeptide Y, and calcitonin gene-related peptide (CGRP) in child patients before and after operation. A total of 80 child patients with congenital heart disease (CHD) complicated with pulmonary hypertension (PH) were enrolled and divided into control group (n = 40, conservative treatment for various reasons) and observation group (n = 40, active preoperative preparation and timely operative intervention) according to different treatments. There were positive correlations between systolic pulmonary arterial pressure (sPAP) and ET-1, plasma neuropeptide Y, while negative correlation between sPAP and CGRP. In conclusion, our data demonstrate that the levels of ET-1, plasma neuropeptide Y, and CGRP in PH-CHD were significantly changed after interventions, which provides new leads as alternative biomarkers to assess the efficacy of treatments against PH-CHD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2020) conducted a cohort in Congenital heart disease complicated with pulmonary hypertension (n=80). Operative intervention vs. Conservative treatment was evaluated on Changes in endothelin-1 (ET-1), plasma neuropeptide Y, and calcitonin gene-related peptide (CGRP). Operative intervention significantly changed the levels of ET-1, plasma neuropeptide Y, and CGRP in children with congenital heart disease complicated by pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: